Compass Therapeutics stock price target maintained at $6 by Stifel
Stifel maintained a Buy rating and $6.00 price target for Compass Therapeutics (CMPX), citing positive regulatory feedback on tovecimig. The stock is down 81% from its 52-week high, trading at $1.31. The company plans a 2027 biologics license application and has a current ratio of 11.22, despite cash burn. Stifel noted undervaluation and upcoming catalysts.
How this was made
The 30-second read
Why it matters
Stifel's reaffirmed Buy rating and $6 target suggest a valuation uplift, but execution risk remains high.
Market read
Analyst coverage may trigger short‑term buying interest in CMPX, though broader market impact is limited.
What to watch
Potential delays in FDA approval and the need for additional financing could hinder upside.
Background
Compass Therapeutics is a micro‑cap biotech developing tovecimig for biliary tract cancer, currently trading far below its 52‑week high.
Ticker impact
Stifel reiterated a Buy rating and maintained a $6 price target for Compass Therapeutics, citing regulatory feedback and pipeline prospects.
Potential modest upside if investors follow the new target.
The rating change is fresh and provides a concrete actionable signal, but the company remains cash‑burn heavy and speculative.
Market effects
May lift sentiment in the small‑cap biotech sector as analysts reassess similar pipeline candidates.
Limited to U.S. biotech investors; no broader regional effect.
Minimal global impact beyond niche biotech investors.
Counterpoint
The stock remains highly speculative with cash‑burn concerns; the rating may be premature.
Key entities
- companyCompass Therapeutics
NASDAQ‑listed biotech developing tovecimig.
- analystStifel
Equity research firm providing the rating.
